Nicotine pouches — small, tobacco-free sachets placed between the lip and gum — have surged in popularity across Canada, and dental professionals are now seeing the oral health consequences in their operatories. As of July 2026, the Canadian Dental Association (CDA) has flagged nicotine pouches as an emerging concern in its latest publications, and dentists across Ontario are reporting increased presentations of localized gum irritation, mucosal lesions, and tissue recession in patients who use these products daily.
The products go by brand names that many of your patients will recognize: Zyn, Velo, On!, and Rogue are among the most common in the Canadian market. They are marketed as smoke-free, spit-free, and discreet alternatives to cigarettes and traditional smokeless tobacco. Patients often perceive them as harmless — a perception that dental professionals are uniquely positioned to correct.
What Are Nicotine Pouches and Why Are They Different?
Nicotine pouches are small, pre-portioned sachets containing nicotine (typically 3 to 12 milligrams per pouch), food-grade fillers, flavourings, and a pH adjuster that enhances nicotine absorption through the oral mucosa. Unlike traditional smokeless tobacco products such as snus or chewing tobacco, nicotine pouches do not contain any tobacco leaf.
This distinction matters for two reasons. First, the absence of tobacco means nicotine pouches are not subject to the same regulatory framework as tobacco products in Canada. Second, the "tobacco-free" label leads many consumers to assume the products carry minimal health risks — an assumption that ignores the pharmacological effects of nicotine itself on oral tissues.
Users place a pouch between the upper lip and gum, typically for 20 to 60 minutes at a time. Heavy users may go through 10 to 20 pouches per day, meaning the oral mucosa in the placement area is exposed to nicotine and other pouch chemicals for the majority of waking hours.
Oral Health Effects: What the Evidence Shows
Research on nicotine pouches specifically is still emerging — these products are relatively new, and long-term longitudinal data does not yet exist. However, the existing evidence, combined with well-established knowledge of nicotine's pharmacological effects on oral tissues, paints a concerning picture that dental professionals should understand.
Localized Gum Tissue Damage
The most visible effect is mechanical and chemical irritation at the placement site. Dental professionals report seeing indentations, grooves, and whitened patches on the gingiva where patients habitually place pouches. A 2024 systematic review published in the journal BMC Oral Health found that nicotine pouch use is associated with localized mucosal changes, including leukoplakia-like lesions and gingival recession, particularly in users who place pouches consistently in the same location.
The mechanical pressure of the pouch itself, combined with the chemical action of nicotine and pH-adjusting agents on the tissue, creates a dual insult. Over time, this can lead to irreversible gingival recession in the affected area.
Vasoconstriction and Reduced Blood Flow
Nicotine is a potent vasoconstrictor. It narrows blood vessels and reduces blood flow to the gingival tissues, impairing the delivery of oxygen and nutrients essential for tissue health and healing. This effect is well documented in smokers, but it applies equally to nicotine delivered through pouches — the delivery method changes, but the pharmacology does not.
For dental professionals, vasoconstriction has a particularly insidious clinical implication: it masks the signs of gum disease. Healthy gingival inflammation — redness, swelling, bleeding on probing — is the body's early warning system for periodontal disease. Nicotine suppresses these inflammatory responses, meaning that periodontal disease can progress silently in nicotine pouch users. A patient's gums may appear pale and firm while attachment loss is occurring beneath the surface.
Xerostomia and Increased Caries Risk
Nicotine stimulates sympathetic nervous system activity, which reduces salivary flow. Chronic nicotine pouch users frequently report dry mouth — a condition that significantly elevates the risk of dental caries. Saliva serves as the mouth's natural defence system: it buffers acids produced by oral bacteria, remineralizes enamel, and physically rinses bacteria from tooth surfaces. When salivary flow is reduced, this defence collapses.
For patients who use nicotine pouches throughout the day, the combination of reduced saliva and the sugars or sweeteners present in many pouch formulations creates an environment that accelerates tooth decay. Dental professionals treating these patients should consider enhanced caries prevention protocols, including more frequent fluoride applications and shorter recall intervals.
Alveolar Bone Loss and Implant Complications
Nicotine impairs osteoblast function — the cells responsible for building and maintaining bone. In the context of dental health, this means that chronic nicotine exposure, regardless of delivery method, increases the risk of alveolar bone loss around teeth and dental implants. Once bone loss occurs in the jaw, it cannot be reversed — it can only be managed.
For patients considering dental implants, nicotine pouch use represents a risk factor for implant failure that practitioners should assess and discuss during treatment planning. The effect is pharmacological, not combustion-related, so switching from cigarettes to nicotine pouches does not eliminate this risk.
Pro Tip: Add nicotine pouch use as a specific question on your medical history form. Many patients will not volunteer this information because they do not consider it a "tobacco product." Asking directly — "Do you use nicotine pouches such as Zyn, Velo, or similar products?" — captures usage that a generic "Do you use tobacco?" question misses.
The Regulatory Landscape in Canada
The regulatory status of nicotine pouches in Canada is complex and evolving. Because these products do not contain tobacco leaf, they fall outside the scope of the Tobacco and Vaping Products Act (TVPA) in their current formulation. Health Canada regulates nicotine replacement therapies (patches, gum, lozenges) under the Food and Drugs Act, but nicotine pouches marketed for recreational use occupy a regulatory grey area.
Some nicotine pouch brands are sold in Canadian convenience stores and gas stations without the health warnings required on tobacco products. Others are available through online retailers. The lack of consistent regulatory oversight means that Canadian consumers may not receive adequate warnings about the oral health risks associated with these products.
Health Canada has indicated that it is monitoring the nicotine pouch market, and regulatory action may be forthcoming. In the interim, dental professionals serve as a critical front-line source of evidence-based information for patients who use these products.
What the CDA Says
The Canadian Dental Association (CDA) addressed nicotine pouches in its 2026 publication CDA Essentials (Volume 13, Issue 3), highlighting the need for dental professionals to be aware of these products and their oral health implications. The CDA's position aligns with its broader stance on nicotine products: that dental professionals should assess nicotine use in all forms during patient intake and provide evidence-based counselling on associated oral health risks.
The CDA does not currently have a standalone position statement on nicotine pouches, but its existing statements on tobacco and nicotine products emphasize the profession's role in patient education and harm reduction counselling.
Patient Counselling: How to Have the Conversation
Many patients who use nicotine pouches genuinely believe they are making a healthier choice than smoking. Approaching the conversation with judgment or alarm is counterproductive. Instead, focus on specific, observable clinical findings and explain the mechanism in plain language.
A Framework for the Clinical Conversation
- Identify the habit. Ask directly during medical history review: "Do you use any nicotine products, including pouches like Zyn or Velo?" Note frequency, duration, and placement site.
- Show the evidence. If you observe mucosal changes, gingival recession, or tissue indentations at the placement site, show the patient with an intraoral camera. Visual evidence is more persuasive than verbal warnings.
- Explain the mechanism. "The nicotine in these pouches reduces blood flow to your gums, which can hide the early signs of gum disease. It also dries out your mouth, which increases your risk of cavities."
- Provide options, not ultimatums. Patients are more receptive to harm reduction than to demands for immediate cessation. Suggest rotating the placement site to distribute tissue exposure, reducing the number of pouches per day, or discussing nicotine reduction strategies with their physician.
- Document and monitor. Record nicotine pouch use in the patient's chart and photograph any mucosal changes at each visit. Longitudinal documentation allows you to track progression and demonstrate changes to the patient over time.
Pro Tip: If a patient is using nicotine pouches as a smoking cessation aid, acknowledge that reducing combustion exposure is a positive step while being transparent about the oral health risks that remain. Referral to a smoking cessation program or physician who can discuss evidence-based nicotine replacement therapies (patches, prescription medications) gives the patient a constructive path forward.
Clinical Protocols for Nicotine Pouch Users
Dental professionals treating patients who use nicotine pouches should consider adjusting their clinical approach:
- Enhanced periodontal assessment: Probe carefully at nicotine pouch placement sites. Remember that vasoconstriction may suppress bleeding on probing, so use attachment levels and radiographic bone levels as primary indicators rather than relying on BOP alone.
- Shorter recall intervals: Consider 3- to 4-month recall intervals for heavy users instead of the standard 6-month cycle, particularly if mucosal changes or early recession are observed.
- Caries prevention: Prescribe high-fluoride toothpaste (5000 ppm) for patients with xerostomia and recommend xylitol-containing products to stimulate salivary flow.
- Implant planning: Discuss nicotine use as a risk factor during implant consultations. While nicotine pouch use is not an absolute contraindication for implant placement, patients should understand that it increases the risk of delayed healing and potential implant failure.
- RCDSO documentation standards: The Royal College of Dental Surgeons of Ontario (RCDSO) requires thorough documentation of patient risk factors. Recording nicotine pouch use, clinical findings, and patient counselling in the chart satisfies this obligation and protects the practitioner in the event of a future dispute.
Prevalence: How Big Is This Issue in Canada?
Comprehensive Canadian prevalence data on nicotine pouch use is limited as of July 2026. The products are relatively new to the Canadian market compared to the United States, where brands like Zyn have experienced rapid growth. Industry analysts have reported significant year-over-year sales increases for nicotine pouches in North America, and Canadian convenience store and online retail channels have expanded their nicotine pouch selections in 2025 and 2026.
Among younger demographics — adults aged 18 to 34 — nicotine pouches appear to have the strongest adoption, driven by social media marketing, peer influence, and the perception that tobacco-free nicotine products are low-risk. Dental professionals in urban centres like Toronto, Mississauga, and Brampton are anecdotally reporting increased presentations of pouch-related mucosal changes, particularly among younger adult patients.
The absence of mandatory reporting or surveillance for nicotine pouch use in Canada means that the full scope of the issue is likely underestimated. Dental professionals who routinely screen for nicotine pouch use contribute to a more accurate understanding of prevalence within their patient populations.
Looking Ahead: What Ontario Dentists Should Watch
Several developments are worth monitoring in the coming months:
- Health Canada regulatory action: If Health Canada moves to regulate nicotine pouches under existing or new legislation, it could affect product availability, marketing, and required health warnings in Canada.
- CDA position statement: A standalone CDA position statement on nicotine pouches would provide dental professionals with an authoritative reference for patient counselling and clinical decision-making.
- Long-term research: As nicotine pouch use matures, longitudinal studies will provide clearer data on the long-term oral health consequences, including cancer risk, which remains an open question for tobacco-free nicotine products.
- Provincial regulatory body guidance: The RCDSO and other provincial regulators may issue specific guidance on screening and documentation requirements for nicotine pouch use as the evidence base grows.
Frequently Asked Questions
Q: Are nicotine pouches safer for oral health than smoking?
Nicotine pouches eliminate the combustion-related risks of smoking, including exposure to tar, carbon monoxide, and many of the carcinogens in cigarette smoke. In that specific sense, they represent a reduction in certain risks. However, they are not "safe" for oral health. The nicotine itself causes vasoconstriction, impairs healing, contributes to gum recession, and increases caries risk through dry mouth. Dental professionals should frame nicotine pouches as "less harmful than cigarettes" rather than "harmless."
Q: Should I refuse to place implants in patients who use nicotine pouches?
Nicotine pouch use is a risk factor for implant complications, not an absolute contraindication. The clinical decision depends on the individual patient's overall health, bone quality, nicotine consumption level, and willingness to reduce or pause use during the healing period. Informed consent should include a clear discussion of how nicotine affects osseointegration and healing outcomes. Document the conversation and the patient's acknowledgment of the risk.
Q: How should I code nicotine pouch-related mucosal lesions for insurance purposes in Ontario?
Mucosal lesions identified during examination should be documented and coded according to the Ontario Dental Association (ODA) fee guide for oral pathology examinations and biopsy procedures where clinically indicated. If a biopsy is performed, standard oral pathology coding applies. For ongoing monitoring of mucosal changes, document the findings under periodic or recall examination notes and photograph lesions for the patient record. Consult the current ODA fee guide for specific procedure codes applicable to your clinical situation.
EBIKO Dental will continue monitoring developments in nicotine pouch regulation and oral health research as the Canadian Dental Association, Health Canada, and the RCDSO provide updated guidance on this emerging issue.